“Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials.”, Lancet, vol. 391, no. 10120, pp. 563-571, 2018.
, “Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial.”, Lancet HIV, vol. 6, no. 5, pp. e297-e306, 2019.
, “Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial.”, Lancet Infect Dis, vol. 19, no. 9, pp. 1013-1022, 2019.
,